brilliant blue g (Coomassie Brilliant Blue) Report issue

Small molecule Imaging Orphan Drug FDA Approved FDA Priority Review FDA
AACT MeSH PubChem

Active Ingredient History

NOW
  • Now
Brilliant Blue G is triphenylmethane dye that was developed for use in the textile industry but is now commonly used for staining proteins in analytical biochemistry. The Bradford assay is a standard, rapid dye-binding assay that uses Brilliant Blue G to quantify the amount of protein in a solution. Brilliant Blue G also acts as a selective inhibitor of the P2X purinoceptor channel P2X7 (IC50s = 10.1 and 265 nM for rat and human P2X7, respectively). In mice, it inhibits interleukin-1β expression and reduces neurological injury secondary to traumatic brain injury. Brilliant Blue G was used to prepare the protein reagent for the determination of protein content of the collagenase enzyme isolated from fish waste. It may be employed as a stain for the internal limiting membrane (ILM) for the macular hole (MH) and epiretinal membrane (ERM) surgery.   NCATS

Chemistry

  • SMILES: [Na+].CCOC1=CC=C(NC2=CC=C(C=C2)C(C3=CC=C(C=C3C)N(CC)CC4=CC=CC(=C4)S([O-])(=O)=O)=C5C=CC(C=C5C)=[N+](CC)CC6=CC=CC(=C6)S([O-])(=O)=O)C=C1
  • InChIKey: RWVGQQGBQSJDQV-UHFFFAOYSA-M
  • Mol. Mass: 854.02
  • ALogP: Missing data
  • ChEMBL Molecules: Missing data
More Chemistry

Pharmacology

Alternative names

acid blue 90 | brilliant blue g | c.i. 42655 | coomassie blue g | coomassie brilliant blue | coomassie brilliant blue g250 | coomassie brilliant blue g 250 | serva blue g | supranol cyanine g | xylene brilliant cyanine g

Organizations (4)

Research & Development (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (4)

Approved Indications (1)


 

Optical Imaging (approved 2019)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Diabetic Retinopathy (Phase 3)

Epiretinal Membrane (Phase 3)

Retinal Perforations (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial Organizations: 2

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue